CN116083294B - Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia - Google Patents
Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia Download PDFInfo
- Publication number
- CN116083294B CN116083294B CN202211469452.5A CN202211469452A CN116083294B CN 116083294 B CN116083294 B CN 116083294B CN 202211469452 A CN202211469452 A CN 202211469452A CN 116083294 B CN116083294 B CN 116083294B
- Authority
- CN
- China
- Prior art keywords
- preeclampsia
- strain
- lactobacillus reuteri
- intestinal
- intestinal flora
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000011461 pre-eclampsia Diseases 0.000 title claims abstract description 70
- 238000002360 preparation method Methods 0.000 title claims description 20
- 241000186604 Lactobacillus reuteri Species 0.000 title abstract description 48
- 229940001882 lactobacillus reuteri Drugs 0.000 title abstract description 48
- 230000000968 intestinal effect Effects 0.000 claims abstract description 48
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000002870 angiogenesis inducing agent Substances 0.000 claims abstract description 14
- 230000002792 vascular Effects 0.000 claims abstract description 10
- 230000001772 anti-angiogenic effect Effects 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 230000001023 pro-angiogenic effect Effects 0.000 claims abstract description 6
- 238000009472 formulation Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 5
- 230000008694 endothelial dysfunction Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 239000002068 microbial inoculum Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 241000186660 Lactobacillus Species 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229940039696 lactobacillus Drugs 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 230000001105 regulatory effect Effects 0.000 abstract description 11
- 208000024891 symptom Diseases 0.000 abstract description 10
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000003511 endothelial effect Effects 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 230000003845 vascular endothelial function Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- 210000002826 placenta Anatomy 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 10
- 210000003754 fetus Anatomy 0.000 description 8
- 230000035935 pregnancy Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000033115 angiogenesis Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000003169 placental effect Effects 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 201000001474 proteinuria Diseases 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 3
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000013588 oral product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 108010082093 Placenta Growth Factor Proteins 0.000 description 2
- 102100035194 Placenta growth factor Human genes 0.000 description 2
- 208000002787 Pregnancy Complications Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000012113 pregnancy disease Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000566145 Otus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000587 angiogenesis modulating agent Substances 0.000 description 1
- 229940076002 angiogenesis modulator Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 230000004578 fetal growth Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000027636 regulation of nitric oxide biosynthetic process Effects 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The application discloses a strain, lactobacillus reuteri (Limosilactobacillus reuteri, CALM 603), with a preservation number of CGMCC No.25407. The strain has outstanding effects in regulating intestinal flora, improving vascular endothelial function, improving preeclampsia symptoms and the like, can effectively balance intestinal microecology after being planted in intestinal tracts, increases intestinal beneficial bacteria, avoids intestinal flora disorder and improves the condition of intestinal flora disorder in preeclampsia; the intervention of lactobacillus reuteri can promote the organism in preeclampsia to produce nitric oxide which is a substance for regulating vascular endothelial activity, inhibit the expression level of anti-angiogenic factors and up-regulate the expression level of pro-angiogenic factors, improve the related symptoms in preeclampsia, and has wide market application prospect.
Description
Technical Field
The application relates to the technical field of medical microorganisms, in particular to lactobacillus reuteri and application thereof in preparation of a preparation product for preventing or treating preeclampsia.
Background
Preeclampsia refers to pregnancy syndrome of pregnant women with normal pre-pregnancy blood pressure, which has clinical symptoms such as hypertension, proteinuria and the like after 20 weeks of pregnancy, is a main cause of morbidity and mortality of mothers and fetuses, seriously endangers the health of babies and infants, but clinically has no effective treatment mode except delivery, and at present, low-dose aspirin is clinically usually given for prevention or magnesium sulfate is given for alleviation when the morbidity.
A large number of researches show that normal intestinal microecology plays a vital role in maintaining human health and resisting diseases, and the intestinal microecology structure of pregnant women can be adaptively adjusted along with the occurrence and development of pregnancy, which is very important for maintaining normal pregnancy ending, and once maladaptation or dysbacteriosis occurs, pregnancy complications such as preeclampsia and the like can be caused. The research shows that the intestinal flora structure of the preeclampsia mice is abnormally changed, the bacterial abundance is obviously reduced, meanwhile, beneficial bacteria are obviously down-regulated, harmful bacteria are obviously increased, and the animal model of fecal bacteria transplantation is utilized to prove that the pregnant mice show typical clinical symptoms of preeclampsia after the preeclampsia patients are transplanted with fecal bacteria.
The probiotic products can improve intestinal microenvironment, but the conditions that the effect of improving preeclampsia by the probiotic products is not stable enough or the curative effect is not exact enough can occur, the components of the probiotic products are relatively complex, the specific beneficial components of the probiotics are not specific, the specific effects are not specific, the conditions that the effect of improving preeclampsia by different probiotic products is not stable enough or the curative effect is not exact enough can occur, and finally the real clinical effect is difficult to ensure.
Disclosure of Invention
The application aims to at least partially overcome the defects of the prior art and provide a strain and application of the strain in preparation of a preparation product for preventing or treating preeclampsia.
In order to achieve the technical purpose, the application adopts the following technical scheme:
a strain, the strainThe strain is Lactobacillus reuteriLimosilactobacillus reuteri) The preservation number of the strain is CGMCC NO.25407.
The use of the strain in the preparation of a formulation product for preventing or treating preeclampsia.
The preparation product is used for improving preeclampsia caused by vascular endothelial dysfunction.
The preparation product is used for regulating alpha diversity and beta diversity of intestinal flora.
The preparation product is used for improving the alpha diversity of intestinal flora. The preparation product is used for reducing colony structure difference of intestinal flora.
The preparation product is used for regulating placenta angiogenesis regulator.
The regulatory factor includes an anti-angiogenic factor, a pro-angiogenic factor, and nitric oxide.
The preparation product is used for inhibiting the expression of anti-angiogenic factors, promoting the expression of pro-angiogenic factors and promoting the synthesis of nitric oxide.
The active ingredient of the preparation product is the microbial inoculum of the strain.
The product comprises a medicament.
Biological preservation information:
lactobacillus reuteri of the applicationLimosilactobacillus reuteriCALM 603) strain, which was preserved in the China general microbiological culture collection center (CGMCC) (address: the preservation number is CGMCC NO.25407 in North Chen Xili No. 1 and 3 in the Chaoyang area of Beijing city.
Compared with the prior art, the application has the following advantages:
1) The strain can maintain intestinal microecology balance by adjusting the intestinal flora structure and the intestinal flora diversity, avoid preeclampsia caused by intestinal flora disorder, and relieve related symptoms by intervention of the strain after preeclampsia.
2) The strain of the application can promote the organism to produce and regulate vascular endothelial active substances and promote the expression of the angiogenesis factors by regulating the angiogenesis regulatory factors, inhibit the expression of the anti-angiogenesis factors, further improve the vascular endothelial cell function and realize the aim of improving preeclampsia.
3) The strain of the application can be used for adding into medicines for industrialized application and has wide market prospect.
Drawings
FIG. 1 is a colony growth morphology of the strain of the present application cultured on MRS plates;
FIG. 2 shows the mass spectrum identification results of the strain of the application;
FIG. 3 is a graph showing the results of intestinal colonization of a preeclampsia mouse model by the strain of the present application;
FIG. 4 is a graph showing the effect of the strain of the present application on the regulation of intestinal flora α diversity in a preeclampsia mouse model;
FIG. 5 is a graph showing the effect of the strain of the present application on the regulation of β -diversity in intestinal flora in a preeclampsia mouse model;
FIG. 6 is a graph showing the effect of the applied strain on the regulation of intestinal flora structure in a preeclampsia mouse model;
FIG. 7 is a graph showing the effect of the strain of the present application on preeclampsia mouse model intervention;
FIG. 8 is a graph showing the effect of the strain of the present application on placental angiogenesis in a pre-eclamptic mouse model;
FIG. 9 is a graph showing the effect of the strain of the present application on placental angiogenesis modulators in a pre-eclamptic mouse model;
FIG. 10 is a graph showing the regulation of nitric oxide synthesis by the strain of the present application in a preeclampsia mouse model.
Detailed Description
The application is described in further detail below with reference to the drawings and detailed description.
Culture and identification of CALM603
Lactobacillus reuteri of the applicationLimosilactobacillus reuteriCALM 603) was obtained by laboratory autonomous isolation screening, 16S rDNA sequencing and mass spectrometry.
Lactobacillus reuteri obtained by laboratory screening was inoculated directly on MRS medium, and the medium was subjected to anaerobic culture at 37 ℃ for 28 hours to obtain growing colonies, as shown in fig. 1.
Extracting a plurality of single colony DNAs, amplifying and measuring the 16S rDNA sequences of the single colony, comparing the sequence of the sequencing results, simultaneously carrying out mass spectrum identification on the strain, and screening through a series of functional experiments to obtain the strain of the application, wherein the strain is Lactobacillus reuteri capable of improving preeclampsia and vascular endothelial functionsLimosilactobacillus reuteriCALM 603), the sequence of the 16S rDNA is shown as SEQ ID N0.1, and the mass spectrum identification result is shown as fig. 2.
CALM603 applied to animal model experiments
ABX gastric lavage treatment is performed on mice to kill intestinal microorganisms in the mice, resulting in relatively sterile mice. ABX gastric lavage treatment refers to the use of antibiotics, typically tetranectins, including vancomycin (vancomycin), penicillin (ampicillin), metronidazole (metronidazole), and neomycin (neomycin sulfate).
(1) 18 female C57BL/6j mice of 8 weeks of age were randomly assigned to control group (CTRL), preeclampsia model group (L-NAME), lactobacillus reuteri intervention group (L-NAME+ L.r), 6 mice per group.
(2) Mice were placed in animal centers for 5 days of acclimatization. After 5 days, based on ABX gavage treatment for 5 consecutive days in all mice, the concentration of the tetrad antibiotic is as follows: vancomycin, 100 mg/kg, neocomycin sulfate, metanidazole and ampicillin, 200 mg/kg.
(3) The mice were pregnant in the cage, during the period of 9.5-17.5 days of gestation, L-NAME (40 mg/kg/day) was subcutaneously injected into the nuchal and dorsum of 9 consecutive days for preeclampsia and Lactobacillus reuteri intervention groups, while the control group was synchronously injected with PBS. Meanwhile, the Lactobacillus reuteri intervention group continuously performs stomach infusion intervention (1 x 10) on 0.5-17.5 days of gestation 9 CFU/mL, 200 ul/day). Mouse faeces were collected on day 17.5 of gestation.
(4) Fecal DNA was extracted using a QIAamp PowerFecal DNA Kit (Qiagen) kit, where the abundance of colonization of the gut by lactobacillus reuteri was detected by qPCR, and the results of the flora were amplified and library constructed based on the V4 segment of the 16S rRNA gene, high throughput sequencing was performed by Illumina MiSeq platform, and finally bioinformatic analysis was performed on the sequencing result data.
As shown in FIG. 3 (in all the figuresL. reuteriAndL.rall represent lactobacillus reuteri shorthand), the abundance of lactobacillus reuteri in the preeclampsia modeling module is significantly lower than that in the control group, while the abundance of lactobacillus reuteri is multiplied in the lactobacillus reuteri intervention group. Therefore, the lactobacillus reuteri has strong in vivo colonization capability, the abundance of the lactobacillus reuteri in the intestinal tract can be effectively changed through the intervention of the lactobacillus reuteri, the content of the lactobacillus reuteri in the intestinal tract is improved, and the microecology of intestinal flora is improved, so that the aim of improving the preeclampsia symptoms is fulfilled.
Alpha diversity refers to diversity within a particular area or ecosystem, and is a comprehensive indicator reflecting richness and uniformity. Alpha diversity is primarily related to two factors: first is the number of individual species, i.e., richness; and secondly, diversity of species, and uniformity in the number of species in a community.
The index of the community richness mainly comprises a Chao1 index, and the larger the Chao1 index is, the higher the richness of the community is; the sampled OUTs represent species type information; PD whole tree is a diversity index calculated based on phylogenetic tree, it constructs the distance of phylogenetic tree with the representative sequence of OTUs in each sample, add the branch length of all representative sequences in a certain sample, thus the value obtained, the larger the value, the higher the community diversity; shannon index comprehensively considers the richness and uniformity of communities, and the higher Shannon index value is, the higher the diversity of communities is indicated.
As shown in fig. 4, the indexes of the pre-eclampsia module were significantly lower than those of the control group and the lactobacillus reuteri intervention group, so that the intestinal flora enrichment and diversity of the module were the lowest; the indexes of the interference group of the lactobacillus reuteri are close to those of the control group, so that the method can be used for effectively improving the richness and diversity of intestinal flora of a preeclampsia mouse through the interference of the lactobacillus reuteri, enabling the intestinal flora to be close to the intestinal environment of a normal organism, maintaining intestinal microecological balance, avoiding intestinal flora disorder and further avoiding pregnancy complications such as preeclampsia.
Beta diversity is often used to compare differences between different ecosystems, reflecting heterogeneity of biological species due to the environment, and in general terms, different treatments (environmental, health, etc.) can lead to changes in the community structure.
As shown in fig. 5, the intestinal flora distribution (beta diversity) of the preeclampsia modeling group is significantly deviated from that of the control group and the intervention group, so that the intestinal flora of the modeling group is significantly different, and the intestinal flora is disordered; the intestinal flora distribution of the lactobacillus reuteri intervention group is obviously regressed compared with that of the control group. Therefore, the interference of lactobacillus reuteri can effectively adjust the difference between intestinal flora, promote the intestinal flora to maintain a stable environment, and avoid the phenomenon of flora disturbance.
As shown in FIG. 6, compared with the control group, the flora structure of the preeclampsia modeling group has obviously reduced intestinal firmicutes and Proteus and increased bacteroides, so that the preeclampsia can influence the intestinal flora structure and deviate the intestinal flora structure; the intestinal flora structure distribution of the Lactobacillus reuteri intervention group is close to that of the control group, the intestinal thick-wall fungus of the mice is increased by the intervention of the Lactobacillus reuteri, and the bacteroides is reduced to be close to that of the control group.
Intervention effect of CALM603 on preeclampsia mouse model
The clinical manifestations of preeclampsia are mainly: hypertension, proteinuria, fetal growth limitation, and pathological lesions of the placenta and kidneys. Therefore, the experiment can evaluate the intervention effect of the lactobacillus reuteri on the preeclampsia according to the clinical manifestation.
As shown in fig. 7, graph a shows that the blood pressure of the preeclampsia modeling group was continuously increased, significantly higher than that of the intervention group and the control group, while the blood pressure of the lactobacillus reuteri intervention group was always leveled with that of the control group, and the blood pressure was not significantly different. Therefore, the condition of hypertension of a preeclampsia mouse can be effectively improved through the intervention of lactobacillus reuteri; the diagram B shows proteinuria, and the diagram shows that the proteinuria of the preeclampsia modeling group is worse than that of the control group and the intervention group, and the proteinuria of a preeclampsia mouse can be effectively improved through the intervention of lactobacillus reuteri, so that the intervention group and the control group tend to be close; the graph C shows the sizes of the placenta and the fetus of the mice, and the placenta and the fetus of the preeclampsia modeling group can be observed to be obviously smaller than those of a control group and an intervention group through naked eyes, and the problems of the sizes of the placenta and the fetus of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri; the graph D shows the weight of the fetus and placenta from left to right, and shows the weight of the fetus and the weight of the placenta, and the graph shows that the interference group and the control group of the lactobacillus reuteri are higher than the preeclampsia modeling group, the data of the interference group are close to the control group, and the weight of the fetus of the preeclampsia mouse can be effectively improved through the interference of the lactobacillus reuteri, so that the normal development of the fetus is facilitated; as shown in a diagram E, the diagram shows the injury condition of the glomerulus of the mice, compared with a control group, the preeclampsia modeling group can obviously observe the abnormal glomerulus structure and endothelial hyperplasia, and the injury condition of the glomerulus of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri; as shown in the diagram F, the diagram shows the damage condition of the placenta of the mice, and the ratio of the placenta labyrinth area of the preeclampsia modeling module to the connecting area is increased, the vascular endothelial hyperplasia of the labyrinth area is observed, and the damage condition of the placenta of the preeclampsia mice can be effectively improved through the intervention of lactobacillus reuteri.
The above results indicate that L-NAME-induced development of preeclampsia symptoms was somewhat alleviated by the intervention of Lactobacillus reuteri, and that each indicator tended to be in normal mice.
Regulating effect of CALM603 on placenta vascular endothelial function of preeclampsia mouse model
As shown in fig. 8, placental vascular endothelial cells were labeled with CD31 (green fluorescence). The graph shows that the interference of the lactobacillus reuteri can effectively improve the generation condition of the placental vascular endothelial cells in preeclampsia, and the lactobacillus reuteri has obvious promotion effect on the placental angiogenesis of the preeclampsia mice.
As shown in FIG. 9, the preeclampsia modeling group has a remarkable promotion effect on the expression of the anti-angiogenic factor sFlt-1 and has an inhibition effect on the expression of the pro-angiogenic factor PlGF; the Lactobacillus reuteri intervention group has an inhibitory effect on the expression of the anti-angiogenic factor sFlt-1, while having an accelerating effect on the expression of the pro-angiogenic factor PlGF. Therefore, the expression of the placenta vascular endothelial function related regulator can be effectively regulated through the intervention of lactobacillus reuteri, the angiogenesis is promoted, the development of the placenta is ensured, and the preeclampsia related symptoms are avoided.
As shown in fig. 10, lactobacillus reuteri has a promoting effect on nitric oxide synthesis in preeclampsia mice. The nitrogen monoxide level in the serum of a preeclampsia mouse can be effectively increased through the intervention of lactobacillus reuteri; lactobacillus reuteri promotes up-regulation of phosphorylation levels of pre-eclamptic mouse placental nitric oxide synthase eNOS (endothelial nitric oxide synthase), where p-eNOS represents phosphorylated eNOS and β -actin represents β actin.
Application of CALM603
The strain can be prepared into a microbial inoculum and applied to medicines, or can be used for intervening preeclampsia and vascular endothelial dysfunction by means of intravenous transfusion or intramuscular injection and the like.
The oral product takes the microbial inoculum of the strain of the application as an active component, and plays the role of improving or treating preeclampsia and vascular endothelial dysfunction after entering a human body through an oral mode. The oral products include, but are not limited to, liquid beverages, extracts, powders, pills, granules/powders, capsules, tablets, pills, and the like, by dosage form classification. In order to realize the formulation, auxiliary materials which can be used in food and pharmaceutical preparations are added in the preparation process: such as fillers, disintegrants, lubricants, suspending agents, binders, sweeteners, flavoring agents, preservatives, and the like. The filler comprises: starch, lactose, mannitol, microcrystalline cellulose, sucrose, xylitol, and the like; the disintegrating agent comprises: starch, microcrystalline cellulose, sodium carboxymethyl starch, low-substituted sodium hydroxypropyl cellulose, and the like; the lubricant comprises: talc, silica, sodium lauryl sulfate, magnesium stearate, and the like; the suspending agent comprises: polyvinylpyrrolidone, microcrystalline cellulose, agar, hydroxymethyl cellulose, and the like; the adhesive comprises: starch slurry, polyvinylpyrrolidone, hydroxymethyl cellulose, and the like; the sweetener comprises: saccharin sodium, aspartame, sucrose, sodium cyclamate, glycyrrhetinic acid, etc.; the flavoring agent comprises: sweetener and various flavors; the preservative comprises: nipagin, benzoic acid, sodium benzoate, benzalkonium bromide, chlorhexidine acetate, eucalyptus oil, sorbic acid and salts thereof, etc. The auxiliary materials are not only used for shaping various dosage forms, but also used for protecting active components of oral products and avoiding inactivation caused by the influence of external environment.
The injection intervention takes the bacterial agent of the strain as an active component, uses sterile water or physiological saline to re-dissolve the bacterial agent or the preparation containing the strain to obtain injection, injection liquid, and plays the effect of improving or treating preeclampsia and vascular endothelial dysfunction after entering a human body through injection or transfusion.
In conclusion, the strain of the application is lactobacillus reuteri @Limosilactobacillus reuteriCALM 603), the preservation number of the strain is CGMCC NO.25407, the bacterial strain is utilized to regulate intestinal microecology so as to achieve the aim of treating preeclampsia, and the bacterial strain has the advantages of low cost, small risk, almost no side effect, easy clinical transformation and the like, and has outstanding effects in regulating intestinal flora, improving vascular endothelial function, improving preeclampsia symptoms and the like. After lactobacillus reuteri is planted in the intestinal tract, intestinal microecology can be effectively balanced, beneficial intestinal bacteria are increased, intestinal flora disturbance is avoided, and the situation of intestinal flora disturbance in preeclampsia is improved; the intervention of lactobacillus reuteri can promote the organism in preeclampsia to produce nitric oxide which is a substance for regulating vascular endothelial activity, up-regulate the expression level of the angiogenesis promoting factors, improve the related symptoms in preeclampsia and have wide market application prospect.
The above embodiments are preferred embodiments of the present application, but are not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principles of the present application should be made therein and are intended to be equivalent substitutions within the scope of the present application.
Claims (8)
1. A strain is Lactobacillus reuteriLimosilactobacillus reuteri) The preservation number of the strain is CGMCC NO.25407.
2. Use of a strain according to claim 1 for the preparation of a formulation product for the prevention or treatment of preeclampsia.
3. The use according to claim 2, wherein the formulation product is for ameliorating preeclampsia caused by vascular endothelial dysfunction.
4. The use according to claim 2, wherein the formulation product is for modulating intestinal flora alpha-diversity and beta-diversity.
5. The use according to claim 4, wherein the formulation product is for increasing intestinal flora alpha diversity; the preparation product is used for reducing colony structure difference of intestinal flora.
6. The use according to claim 2, wherein the formulation product is for inhibiting the expression of an anti-angiogenic factor, promoting the expression of a pro-angiogenic factor and promoting nitric oxide synthesis.
7. The use according to claim 2, wherein the active ingredient of the formulated product is a microbial inoculum of the strain.
8. The use of claim 2, wherein the formulation product comprises a medicament.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211469452.5A CN116083294B (en) | 2022-11-22 | 2022-11-22 | Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211469452.5A CN116083294B (en) | 2022-11-22 | 2022-11-22 | Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116083294A CN116083294A (en) | 2023-05-09 |
CN116083294B true CN116083294B (en) | 2023-10-13 |
Family
ID=86198166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211469452.5A Active CN116083294B (en) | 2022-11-22 | 2022-11-22 | Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116083294B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265553A (en) * | 2020-01-23 | 2020-06-12 | 湖南菲勒生物技术有限公司 | Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions |
CN114410533A (en) * | 2022-01-27 | 2022-04-29 | 江南大学 | Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170020930A1 (en) * | 2015-07-21 | 2017-01-26 | Therapeutic Solutions International, Inc. | Prevention of pregnancy complications by probiotic administration |
-
2022
- 2022-11-22 CN CN202211469452.5A patent/CN116083294B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111265553A (en) * | 2020-01-23 | 2020-06-12 | 湖南菲勒生物技术有限公司 | Application of lactobacillus reuteri from breast milk to adjustment of maternal and infant immune functions |
CN114410533A (en) * | 2022-01-27 | 2022-04-29 | 江南大学 | Application of lactobacillus reuteri CCFM1040 in relieving and preventing atherosclerosis |
Non-Patent Citations (3)
Title |
---|
Efficacy of Direct or Indirect Use of Probiotics for the Improvement of Maternal Depression during Pregnancy and in the Postnatal Period: A Systematic Review and Meta-Analysis;Klavdija Cˇ ucˇek Trifkovic et al.;Healthcare;第10卷(第970期);第1-16页 * |
Limosilactobacillus reuteri ameliorates preeclampsia in mice via improving gut dysbiosis and endothelial dysfunction;Bingyu Li et al.;Biomedicine &Pharmacotherapy;第161卷;第1-10页 * |
罗伊氏乳杆菌的益生功能;庞洁等;中国生物工程杂志;第31卷(第5期);第131-137页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116083294A (en) | 2023-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110101722B (en) | Application of composite probiotic preparation in preparation of product for treating ulcerative colitis | |
Eykyn et al. | Metronidazole and anaerobic sepsis. | |
EP2415475B1 (en) | Pharmaceutical composition comprising a proton pump inhibitor and a prebiotic for the treatment of ulcerous lesions of the stomach and duodenum | |
CN109402002B (en) | Lactobacillus gasseri and application thereof in preparation of premature delivery prevention medicine | |
MacFarlane et al. | Bacteraemia in diabetics | |
CN115109734B (en) | Lactobacillus agilis B13T4 with function of relieving hyperuricemia and application thereof | |
CN116083325B (en) | Lactobacillus rhamnosus for improving helicobacter pylori related gastrointestinal diseases and application thereof | |
WO2005030230A1 (en) | Compositions and methods for treatment or prevention of psoriasis and related disorders | |
CN113717883B (en) | Lactobacillus plantarum FLPL05 for promoting body health and longevity and application thereof | |
CN114469986A (en) | Application of bacteroides fragilis capsular polysaccharide A and immune checkpoint inhibitor in preparation of medicine for treating digestive system tumor | |
CN114287633A (en) | Probiotic composition containing cranberry and application of probiotic composition in resisting helicobacter pylori | |
CN116083294B (en) | Lactobacillus reuteri and application thereof in preparation of preparation product for preventing or treating preeclampsia | |
CN111154682B (en) | Lactobacillus rhamnosus, microbial agent and food product | |
CN112322553A (en) | Clostridium difficile resistant lactococcus lactis and application thereof | |
CN115466699B (en) | Panda-derived lactobacillus salivarius and application thereof in treating or preventing inflammatory bowel diseases | |
CN114672436A (en) | Lactobacillus acidophilus and application thereof | |
WO2022137239A1 (en) | Methods for modulating microbial populations | |
CN109954004B (en) | Application of bacteroides fragilis extract in preparation of composition for preventing and treating psoriasis | |
CN117106622B (en) | Lactobacillus plantarum and application of composition thereof in preparation of medicines for treating internal hemorrhoids | |
CN116376770B (en) | Application of lactobacillus rhamnosus RH0121 in preparation of hypoglycemic products | |
CN114028380A (en) | Application of naringenin in preparing medicine for treating intestinal flora disorder caused by ovarian cancer | |
TWI780460B (en) | A use of manufacturing a composition of lactobacillus paracasei gks6 for preventing and treating the renal function impairment | |
CN111471610B (en) | Lactobacillus salivarius for relieving pharyngitis | |
CN117946949B (en) | Acremonium muciniphilum and application thereof | |
CN117343880A (en) | Saliva host-associated lactobacillus and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |